ArticleScientific reports2026
Thioredoxin protects against diabetic hearing loss by regulating TOMM22 mediated mitochondrial autophagy in hair cells and inhibiting microglial M1 polarization.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Hearing loss is a prevalent yet mechanistically unclear complication of diabetes. This research aims to systematically investigate the role of thioredoxin (Trx) in diabetic hearing loss and elucidate its underlying molecular mechanisms through clinical, bioinformatics, and experimental analyses. Clinically, elevated serum Trx levels were associated with decreased otoacoustic emission (OAE) parameters, suggesting its potential as a serum biomarker. Bioinformatics analysis revealed that TOMM22 is critical for mitophagy. In vivo, Trx overexpression effectively mitigated the hyperactivation of apoptosis, mitophagy, and M1 microglial activation in diabetic mouse cochlear tissue. An in vitro advanced glycation end-product (AGE)-induced HEI-OC1 cell model demonstrated that Trx1 overexpression inhibited PINK1/Parkin-mediated mitophagy, increased the mitochondrial membrane potential, and reduced apoptosis by maintaining TOMM22 expression. Conversely, CCCP-mediated inhibition of TOMM22 reversed the protective effects of Trx1. Moreover, Trx1 drove microglial polarization towards the anti-inflammatory M2 phenotype. Furthermore, coculture of microglia conditioned medium with HEI-OC1 cells confirmed that Trx1 indirectly protects auditory cells. Thus, Trx protects hearing via dual mechanisms: cell autonomously by regulating the TOMM22/PINK1 axis to maintain mitochondrial homeostasis and noncell autonomously by inducing microglial M2 polarization to improve the auditory microenvironment. These findings provide novel insights into diabetic hearing loss pathogenesis and identify Trx as a potential therapeutic target.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.